Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–12. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Weledji EP, Enoworock G, Mokake M, Sinju M. How Grim is Pancreatic Cancer? Oncol Rev. e-pub ahead of print 2016/07/30. 2016;10(1):294. doi:10.4081/oncol.2016.294.
   PubMedGoogle Scholar
• Gnanamony M, Gondi CS. Chemoresistance in pancreatic cancer: emerging concepts. Oncol Lett. e-pub ahead of print 2017/04/30. 2017;13(4):2507–2513. doi:10.3892/ol.2017.5777.
   PubMed Web of Science ®Google Scholar
• Lum LG, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, Fields K, Dufrense M, Philip P, Dyson G, et al. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology. 2020;9(1):1773201. e-pub ahead of print 2020/09/18. doi:10.1080/2162402X.2020.1773201.
   PubMed Web of Science ®Google Scholar
• Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, Yakobson A, Orevi M, Caplan N, Peretz T, et al. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study. Front Oncol e-pub ahead of print 2020/03/03. 2020;10:70. doi:10.3389/fonc.2020.00070.
   PubMed Web of Science ®Google Scholar
• Kato K, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, et al. Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. Anticancer Res. 2020;40(4):2247–2255. e-pub ahead of print 2020/04/03. doi:10.21873/anticanres.14187.
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. e-pub ahead of print 2004/08/26. 2004;10(16):5316–5326. doi:10.1158/1078-0432.CCR-04-0497.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, et al. . Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005;11(12):4430–4436. e-pub ahead of print 2005/06/17. doi:10.1158/1078-0432.CCR-04-2111.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee J-H et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006 e-pub ahead of print 2006/02/10;12(3):878–887. doi:10.1158/1078-0432.CCR-05-2013.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12(4):1260–1269. e-pub ahead of print 2006/02/21. doi:10.1158/1078-0432.CCR-05-2059.
   PubMed Web of Science ®Google Scholar
• Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Science. 2008;99(4):653–658. doi:10.1111/j.1349-7006.2008.00747.x. e-pub ahead of print 2008/04/02
   PubMed Web of Science ®Google Scholar
• Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34(4):378–390. doi:10.1016/j.ctrv.2008.01.007. e-pub ahead of print 2008/03/28
   PubMed Web of Science ®Google Scholar
• Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: what is the way forward? World J Gastroenterol. 2018;24(29):3222–3238. doi:10.3748/wjg.v24.i29.3222. e-pub ahead of print 2018/08/10
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3–29. doi:10.1016/s0169-409x(02)00169-2. e-pub ahead of print 2003/01/22
   PubMed Web of Science ®Google Scholar
• Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003;22(47):7537–7552. doi:10.1038/sj.onc.1206953. e-pub ahead of print 2003/10/25
   PubMed Web of Science ®Google Scholar
• Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008;65(20):3145–3167. doi:10.1007/s00018-008-8111-5. e-pub ahead of print 2008/06/27
   PubMed Web of Science ®Google Scholar
• Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW, Friess H, Keppler D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer. 2005;115(3):359–367. doi:10.1002/ijc.20831. e-pub ahead of print 2005/02/03
   PubMed Web of Science ®Google Scholar
• Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG. Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+Tumors. J Hematother Stem Cell Res. 2001;10(2):247–260. doi:10.1089/15258160151134944.
   PubMedGoogle Scholar
• Thakur A, Lum LG. In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer. Oncoimmunology. 2016;5(3):e1055061. doi:10.1080/2162402X.2015.1055061. e-pub ahead of print 2016/05/04
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Rosell R. Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res. 2015;4(6):689–703. doi:10.3978/j..2218-6751.2015.12.11. e-pub ahead of print 2016/01/23
   PubMedGoogle Scholar
• Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A. 2019;116(4):1370–1377. e-pub ahead of print 2019/01/10. doi:10.1073/pnas.1816262116.
   PubMed Web of Science ®Google Scholar
• Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017;18(12):2574. doi:10.3390/ijms18122574. e-pub ahead of print 2017/12/02
   PubMed Web of Science ®Google Scholar
• Sasaki N, Ishiwata T, Hasegawa F, Michishita M, Kawai H, Matsuda Y, Arai T, Ishikawa N, Aida J, Takubo K, et al. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. Cancer Sci. 2018;109(4):1135–1146. e-pub ahead of print 2018/02/15. doi:10.1111/cas.13533.
   PubMed Web of Science ®Google Scholar
• Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018;2018:5416923. e-pub ahead of print 2018/04/24. doi:10.1155/2018/5416923.
   PubMed Web of Science ®Google Scholar
• Hagmann W, Jesnowski R, Lohr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010;12(9):740–747. doi:10.1593/neo.10576. e-pub ahead of print 2010/09/09
   PubMed Web of Science ®Google Scholar
• Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: current and Evolving Therapies. Int J Mol Sci. 2017;18(7):1338. doi:10.3390/ijms18071338. e-pub ahead of print 2017/06/24
   PubMed Web of Science ®Google Scholar
• Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011;15(7):817–828. doi:10.1517/14728222.2011.566216. e-pub ahead of print 2011/03/12
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu M, Aneja R, Chandra R, Lage H, Joshi HC. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res. 2006;66(1):445–452. doi:10.1158/0008-5472.CAN-05-1779. e-pub ahead of print 2006/01/07
   PubMed Web of Science ®Google Scholar
• Abele R, Tampe R. Moving the Cellular Peptidome by Transporters. Front Cell Dev Biol. 2018;6:43. e-pub ahead of print 2018/05/16. doi:10.3389/fcell.2018.00043.
   PubMed Web of Science ®Google Scholar
• Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol. 2009;183(10):6800–6807. doi:10.4049/jimmunol.0901747. e-pub ahead of print 2009/10/23
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G,  Wang X,  Dong Z,et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. e-pub ahead of print 2020/04/17. doi:10.1038/s41392-020-0110-5.
   PubMed Web of Science ®Google Scholar
• Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells–much more complex than expected. Mol Cancer. 2011;10(1):128. doi:10.1186/1476-4598-10-128. e-pub ahead of print 2011/10/13
   PubMed Web of Science ®Google Scholar